文献速递银屑病与炎症性皮肤病

Deucravacitinib对比安慰剂和阿普司特治疗中重度斑块状银屑病:52周随机双盲安慰剂对照3期POETYK PSO-1试验的疗效和安全性结果

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
PubMed 文献 · J Am Acad Dermatol · 2022-07-09

POETYK PSO-1试验将中重度斑块状银屑病成人患者按2:1:1随机分配至deucravacitinib 6 mg每日一次组(n=332)、安慰剂组(n=166)或阿普司特30 mg每日两次组(n=168),治疗52周。第16周时,deucravacitinib组PASI 75和sPGA 0/1应答率均显著高于安慰剂组和阿普司特组,疗效持续至第52周,不良事件发生率与两对照组相似。

要点

  • 第16周PASI 75应答率:deucravacitinib组58.4% vs 安慰剂组12.7% vs 阿普司特组35.1%(P<.0001)。
  • 第16周sPGA 0/1应答率:deucravacitinib组53.6% vs 安慰剂组7.2% vs 阿普司特组32.1%(P<.0001)。
  • deucravacitinib不良事件发生率与安慰剂和阿普司特相似,疗效维持至第52周。

核心结论

  • Deucravacitinib在多个疗效终点上优于安慰剂和阿普司特,且在中重度斑块状银屑病中耐受良好。

研究设计与样本

  • 52周、随机、双盲、安慰剂对照3期POETYK PSO-1试验(NCT03624127),中重度斑块状银屑病成人患者按2:1:1随机分配至deucravacitinib 6 mg每日一次组(n=332)、安慰剂组(n=166)或阿普司特30 mg每日两次组(n=168)。

主要发现

  • 第16周PASI 75应答率:deucravacitinib组194例(58.4%)vs 安慰剂组21例(12.7%)vs 阿普司特组59例(35.1%),P<.0001。
  • 第16周sPGA 0/1应答率:deucravacitinib组178例(53.6%)vs 安慰剂组12例(7.2%)vs 阿普司特组54例(32.1%),P<.0001。
  • 疗效在第16周后继续改善并维持至第52周。
  • deucravacitinib不良事件发生率与安慰剂和阿普司特相似。

局限性

  • 研究 Duration 为一年。
  • 种族多样性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed. OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis. METHODS: Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary end points included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at week 16. RESULTS: At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001). Efficacy improved beyond week 16 and was maintained through week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast. LIMITATIONS: One-year duration, limited racial diversity. CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022. PMID: 35820547. doi:10.1016/j.jaad.2022.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。